期刊
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE
卷 1852, 期 6, 页码 1124-1136出版社
ELSEVIER
DOI: 10.1016/j.bbadis.2014.12.024
关键词
Resveratrol; Inflammation; Metabolism; In vitro; In vivo; Clinical trial
资金
- Toyota Foundation
- Elvira and Rasmus Riisfort Foundation
- Ejnar Danielsens Foundation
- AP Moller Maersk Foundation
- Danish Council for Strategic Research [10-093499]
Throughout the Western world obesity prevalence is steadily increasing, and associated metabolic comorbidities are projected to rise during the years to come. As weight loss and weight maintenance remains a major problem, new strategies to protect against obesity-related morbidity are needed. There is a clear association between obesity, low-grade inflammation and obesity-associated diseases, thus, the development of new anti-inflammatory substances is urgently needed as these may ultimately pave the way for novel treatments of obesity and lifestyle-related diseases. A candidate molecule is the polyphenolic compound resveratrol, and in the present review, we provide an overview of the field, and discuss the future scientific perspectives. This article is part of a Special Issue entitled: Resveratrol: Challenges in translating pre-clinical findings to improved patient outcomes. (C) 2015 Elsevier B.V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据